A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With NEWLY DIAGNOSED MULTIPLE MYELOMA NOT TREATED WITH STEM CELL TRANSPLANTATION

STUDY GOAL: To determine whether investigational ixazomib maintenance therapy improves survival in patients with newly diagnosed multiple myeloma who have had a major response to initial therapy and who have not had a stem cell transplant.

Learn more about this study

YOU MAY BE ELIGIBLE
TO PARTICIPATE IF YOU:

  • Are newly diagnosed with multiple myeloma (MM)
  • Have received initial therapy for 6 to 12 months and achieved a major response
  • Have not had a stem cell transplant
  • Are 18 years of age or older
  • Meet other eligibility criteria
LEARN MORE ABOUT ELIGIBILITY CRITERIA

ABOUT MULTIPLE
MYELOMA

An overview of the condition,
its symptoms, and
whom it affects.

GO

WHAT IS A
CLINICAL STUDY?

Learn about the purpose
of clinical studies, how
they are set up, and
why they are important.

GO
We want to answer your questions about this study, but our office is closed now.
Would you like us to call you back?
1-844-622-8532
Monday–Friday 9am–7pm ET